Nonalcoholic fatty liver disease

Gastroenterology

Volumn 122, Issue 6, 2002, Pages 1649-1657

  Clark, Jeanne M ^a   Brancati, Frederick L ^a   Diehl, Anna Mae ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLISM; CHRONIC LIVER DISEASE; DYSLIPIDEMIA; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER INJURY; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0036090972     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.33573     Document Type: Article

References (79)

1. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
2. Test validity of periodic liver function tests in a population of Japanese male bank employees
3. Prevalence of chronic liver disease in the general population of northern Italy: The Dyonisos study
4. Prevalence of and risk factors for hepatic steatosis in Northern Italy
5. Liver fibrosis in overweight patients
6. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology
7. Liver in obesity
8. Liver function in moderate obesity: Study in 534 moderately obese subjects among 4613 male company employees
9. Liver pathology in morbidly obese patients with and without diabetes
10. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
11. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease
12. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
13. Insulin resistance-associated hepatic iron overload
14. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis
15. Quantitative estimation of attenuation in ultrasound video images: Correlation with histology in diffuse liver disease
16. Dual-energy CT in the diagnosis and quantification of fatty liver limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload
17. Noninvasive in vivo quantitative assessment of fat content in human liver
18. Measurement of intracellular triglyceride stores by H spectroscopy and validation in vivo
19. Liver biopsy
20. Nonalcoholic steatohepatitis
21. Clinical features and natural history of nonalcoholic steatosis syndromes
22. Evaluation of abnormal liver enzyme results in asymptomatic patients
23. Nonalcoholic steatohepatitis: An expanded clinical entity
24. Steatohepatitis associated with limb lipodystrophy
25. Excess weight risk factor for alcoholic liver disease
26. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis
27. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis
28. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease
29. Obesity and hepatotoxin risk factors for fatty liver disease
30. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers
31. Fatty infiltration of liver inhyperlipidemic patients
32. Nonalcoholic fatty liver: Another feature of the metabolic syndrome?
33. Liver pathology and the metabolic syndrome X in severe obesity
34. Association of nonalcoholic fatty liver disease with insulin resistance
35. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance
36. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta
37. Prevention of fat-induced insulin resistance by salicylate
38. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 Years after mass hepatitis B vaccination
39. Cause-specific mortality in a population-based study of diabetes
40. The prevalence of hepatitis C virus infection in the United States: 1988-1994
41. Prevalence of fatty liver in a general population of Okinawa, Japan
42. Natural history of alcoholic hepatitis III: Histologic changes
43. Histologic course of alcoholic hepatitis: Influence of abstinence, sex, and extent of hepatic damage
44. Compensated cirrhosis: Natural history and prognostic factors
45. Deaths and hospitalizations from chronic liver disease and cirrhosis - United States, 1980-1989
46. Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C
47. Alcohol-like liver disease in nonalcoholics: A clinical and histopathological comparison with alcohol-induced liver injury
48. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients followed for up to 21 years
49. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity
50. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
51. Thin chance for fat people (to become living donors)
52. Diet and exercise dramatically delay type 2 diabetes; diabetes medication, metformin
53. Effect of weight reduction on hepatic abnormalities in overweight patients
54. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
55. Fasting in obesity: Another cause of liver injury with alcoholic hyaline?
56. Fatty liver induced in Zucker "fatty" (ff) rats by a semisynthetic diet rich in sucrose
57. Morphological changes of organs after sucrose or fructose feeding
58. High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat
59. Insulin resistance: Mechanisms, syndromes, and implications
60. Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice
61. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets
62. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
63. Metformin in non-alcoholic steatohepatitis
64. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
65. Incidence of lactic acidosis in metformin users
66. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
67. Effect of two synthetic antioxidants, vitamin E and ascorbic acid, on the choline-deficient rat
68. Effects of long-term vitamin E supplementation in alcoholic cirrhotics
69. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease
70. Vitamin E treatment of non-alcoholic steatohepatitis in children: A pilot study
71. The effect of betaine in reversing alcoholic steatosis
72. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
73. Metformin enhances certain insulin actions in cultured rat hepatoma cells
74. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells
75. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
76. A controlled trial of gemfibrozil in the treatment of patients with noalcoholic steatohepatitis
77. Atorvastin for the treatment of NASH